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Echocardiography for the “Superior Doctor”
A Call to Action in the Management of Heart Failure*
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lThe superior doctor prevents sickness;
the mediocre doctor attends to impending sickness;
the inferior doctor treats actual sickness.
—Extract from 1st Chinese Medical Text. Attrib-
uted to Huang Dee Nai-Chan, circa 2600 B.C. (1)
The burden of clinically overt heart failure is
likely to increase with our aging population and
escalating rates of obesity and diabetes in the
community. Whether this burden can be effec-
tively reduced by screening efforts remains to be
determined. To be appropriate for screening, a
disease should be serious, and the preclinical
See page 131
phase of the disease should have a sufficiently high
prevalence among the population targeted for
screening. Furthermore, screening initiated before a
critical point in the natural history of the disease
should result in treatment being initiated before the
onset of symptoms. This treatment should be more
beneficial in reducing morbidity or mortality than
treatment given after symptoms develop. Finally,
the screening for the disease should not result in a
significant incidence of “pseudodisease.” On the
basis of these characteristics, it would appear that
there is insufficient evidence to support widespread
screening for preclinical (Stage B) heart failure in
the community. In particular, although pharmaco-
therapy for patients with reduced left ventricular
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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National University, Canberra, Australia. Dr. Abhayaratna has reportedf
that he has no relationships relevant to the contents of this paper to
disclose.LV) ejection fraction (EF) has been shown to
educe morbidity and mortality (2), the prevalence
f this condition in the community is too low to
ustify a screening program in an unselected popu-
ation (3). Furthermore, there is evidence from
ommunity-based studies to suggest a change in
he epidemiology of heart failure to the extent
hat heart failure cases are increasingly likely to
ave preserved LVEF (4). This observation is
obering, given the findings from clinical trials,
hich indicate that, as opposed to heart failure
ith reduced LVEF, pharmacotherapy with a
ariety of neurohumoral modulating agents is not
fficacious in reducing the morbidity and mortal-
ty in patients with heart failure and preserved
VEF (4).
The clinical utility of a biomarker for heart failure
creening can be judged according to the satisfac-
ion of 3 key criteria (5). First, the proposed
iomarker must be accessible, reliable, and afford-
ble. Second, the marker must provide incremental
nformation about cardiac function and prognosis
hat would not otherwise be available. Finally,
atient management with the biomarker should
esult in improved clinical outcomes. Although
bservational studies have previously shown that
tructural heart disease and pre-clinical LV dys-
unction detectable by echocardiography are
trongly associated with elevated natriuretic peptide
evels (6), and that both screening tools are highly
redictive of risk for incident heart failure in large
ohort studies (7,8), there are no studies that have
ssessed their incremental value for heart failure risk
tratification when added to a validated clinical risk
core.
In this issue of iJACC, Kalogeropoulos et al.
9) have taken an important step toward estab-
ishing the role of echocardiography in screening
or heart failure. Using a CHS (Cardiovascular
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142Heart Study) cohort of elderly adults in which
prevalent heart failure cases were excluded (10),
the authors examined the incremental value of
echocardiographic measures and an elevated
N-terminal pro–B-type natriuretic peptide (NT-
proBNP) level when added to a clinical heart
failure risk score for the prediction of hospital-
ization for incident heart failure over a 5-year
period. This study adds to the body of work from
the group, who have previously developed the
“Health, Aging and Body Composition” (Health
ABC) Heart Failure clinical risk score in a
healthy elderly cohort (11), subsequently vali-
dated the clinical risk score in the CHS cohort
(12), and identified the NT-proBNP level 190
g/ml as the optimal discriminatory limit for the
rediction of heart failure risk and cardiovascular
ortality in the same cohort (8). In the current
study (9), the authors elegantly demonstrate that
echocardiographic findings of reduced LVEF,
markers of LV diastolic dysfunction including
abnormal mitral E/A ratio and an increased left
atrial diameter, and increased LV mass; and an
elevated NT-proBNP level were independent
predictors of future hospitalization for heart fail-
ure. Importantly, the authors have established the
enhanced discriminatory ability of adding the
weighted sum of independent echocardiographic
predictors to construct an echocardiographic
score. They conclude that subjects at intermedi-
ate risk of hospitalization for incident heart
failure according to the clinical risk score derived
the most benefit through reclassification of heart
failure by echocardiography and NT-proBNP. In
contrast, echocardiographic screening with a
“subclinical disease” approach or the inclusion of
low-risk patients by clinical risk scoring in the
echocardiographic screening strategy would add
little to identify individuals at risk for heartShekelle PG. Cost-effectiveness of screen- 113:2335–62.tions with regard to the echocardiographic meth-
ods, including the relatively crude estimation of
diastolic function by Doppler methods and as-
sessment of left atrial size by diameter rather than
volume. Indeed, the inclusion of contemporary
measures that constitute a more comprehensive
assessment of diastolic function grade and the
assessment of left atrial volume may have signif-
icantly attenuated the incremental value of NT-
proBNP for the stratification of heart failure risk.
The findings from this study provide a solid
platform for further research into the establish-
ment of echocardiography as an essential tool for
the “superior doctor,” whose goal is to prevent
“sickness” from clinically manifest heart failure.
Specifically, randomized clinical trials will be
required to assess whether the use of echocardi-
ography in concert with natriuretic peptides can
be used to identify patients who are at least
intermediate risk for incident heart failure by
clinical risk scoring, and would benefit from
aggressive risk factor modification and pharma-
cotherapy with neurohumoral modulators. Given
our growing challenge to maximize health gains
with limited healthcare resources, such studies should
be designed with a view to addressing the key question
of “at what cost” through a robust economic evalua-
tion. The observational component of these studies is
likely to provide essential data on the natural history of
heart failure, and to address the concern that the
screening strategies may inadvertently result in a
significant incidence of “pseudodisease” with the con-
sequent negative effects on both physical and psycho-
logical health and well-being.
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